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Abstract
Background: Severe haemophilia is associated with major psychological and economic burden for patients,
caregivers, and the wider health care system. This burden has been quantified and documented for a number of
European countries in recent years. However, few studies have taken a standardised methodology across multiple
countries simultaneously, and sought to amalgamate all three levels of burden for severe disease. The overall aim of
the ‘Cost of Haemophilia in Europe: a Socioeconomic Survey’ (CHESS) study was to capture the annualised
economic and psychosocial burden of severe haemophilia in five European countries.
A cross-section of haemophilia specialists (surveyed between January and April 2015) provided demographic and
clinical information and 12-month ambulatory and secondary care activity for patients via an online survey. In turn,
patients provided corresponding direct and indirect non-medical cost information, including work loss and out-of-
pocket expenses, as well as information on quality of life and adherence. The direct and indirect costs for the
patient sample were calculated and extrapolated to population level.
Results: Clinical reports for a total of 1,285 patients were received. Five hundred and fifty-two patients (43% of the
sample) provided information on indirect costs and health-related quality of life via the PSC. The total annual cost
of severe haemophilia across the five countries for 2014 was estimated at EUR 1.4 billion, or just under EUR 200,000
per patient. The highest per-patient costs were in Germany (mean EUR 319,024) and the lowest were in the United
Kingdom (mean EUR 129,365), with a study average of EUR 199,541. As expected, consumption of clotting factor
replacement therapy represented the vast majority of costs (up to 99%). Indirect costs are driven by patient and
caregiver work loss.
Conclusions: The results of the CHESS study reflect previous research findings suggesting that costs of factor
replacement therapy account for the vast majority of the cost burden in severe haemophilia. However, the
importance of the indirect impact of haemophilia on the patient and family should not be overlooked. The CHESS
study highlights the benefits of observational study methodologies in capturing a ‘snapshot’ of information for
patients with rare diseases.
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Background
Haemophilia is a genetic disorder characterised by a defi-
ciency of a clotting factor in the blood, leading to prolonged
bleed events. The disease is carried on the X chromosome
and primarily affects males, though female carriers of the
gene may exhibit symptoms of mild haemophilia. The two
forms of the condition are Haemophilia A (Factor VIII
(FVIII) deficiency) and Haemophilia B (Factor IX (FIX)
deficiency); Haemophilia A is approximately four times
more common than Haemophilia B [1]. The global inci-
dence of haemophilia is approximately 1 per 4,000–5,000
male births; in a given year, approximately 400 boys are
born with haemophilia in Europe [1].
Individuals with severe haemophilia – representing
approximately one-third of the haemophilia population
in Europe [2, 3] – have factor levels less than 1% of that
expected in a healthy person. Such individuals will
experience recurrent, spontaneous bleeds, often in the
absence of any trauma event [4]; four-fifths of bleed
events occur within the musculoskeletal system [5].
Approximately 90% of people with severe haemophilia
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experience chronic haemophilic joint disease, charac-
terised by chronic inflammation and progressive joint
deformity, in one or more major joints by the age of 30
[5]. As well as joint stiffness and diminished range of
motion, individuals with haemophilia experience signifi-
cant acute pain during bleed events and chronic pain
due to arthropathy, leading to disability and impaired
quality of life in more than half of cases [6].
Prior to the 1960s, when clotting factor replacement
therapy (CFRT) became widely available, life expectancy
of persons with haemophilia (PWH) was very low
(<30 years) in comparison to that of the general male
population, with haemorrhage as the most prevalent
cause of death [2]. Innovations in factor production
mean that PWH in nations with developed healthcare
systems can now expect a near-normal quality of life
and an average lifespan no more than 10 years shorter
than that of an unaffected individual [3, 4]. In this
current “golden era” of haemophilia care [5], manage-
ment of age-related conditions has become a novel
necessity for clinicians and PWH [6, 7]. Nevertheless, a
continuing major risk associated with the use of CFRT is
the development of inhibitors, so-called due to the devel-
opment of antibodies that inhibit factor uptake. Affected
individuals experience poor bleed control and subse-
quently higher levels of morbidity and mortality [8] and
reduced HRQoL [9, 10]. The cost of treating an individual
with an inhibitor can exceed EUR 1 million per year, with
regimens of immune tolerance induction (ITI) therapy
lasting more than 3 years in rare cases [11, 12].
The objective of the CHESS study was to estimate and
extrapolate resource use, costs, and health-related quality
of life (HRQOL) for adults with severe haemophilia in the
five largest European economies (EU5: France, Germany,
Italy, Spain and the United Kingdom (UK)). The psycho-
logical, societal, and economic burden of haemophilia has
been documented for a number of European countries
[13–17]; few studies have taken a standardised method-
ology across multiple countries simultaneously [18], and
sought to amalgamate all three levels of burden for severe
disease. The overall aim of the CHESS study was to
capture the annualised economic and psychosocial burden
of severe haemophilia in the EU5.
Methods
Study cohort
The study population is a sample of adult patients
(18 years and over) with severe inherited haemophilia A
or B (FVIII/FIX level <1 IU dL−1), drawn approximately
in proportion to the population of individuals with
haemophilia in each of the five countries participating.
Individuals with acquired haemophilia or other clotting
factor deficiencies (e.g. von Willebrand disease (VWD),
haemophilia C) were excluded, as symptoms of vWD are
generally comparable to that of mild or moderate haemo-
philia [19], and our sample size would preclude meaningful
conclusions for other rare coagulation disorders.
Study design
A retrospective, cross-sectional methodology was employed.
Data was collected by means of two questionnaires, de-
signed specifically for specialists and patients: the web-based
case record forms (CRFs) were used to collect information
on direct medical resource utilisation and clinical data based
on recorded notes; and the paper patient self-completion
form (PSC), given to patients following the consultation,
provided complimentary socio-economic information. One
hundred and thirty-nine haematologists (and haemophilia
care providers (HCPs) in France) based in hospitals and
clinics completed up to eight patient CRFs, with a small
number providing information for up to 16 patients. In
order to minimise the risk of selection bias, physicians were
encouraged to recruit the next eligible patients with whom
they consulted, irrespective of their reason for consultation.
All patient participants provided informed consent.
The study protocol was approved by the Research Ethics
Sub Committee of the Faculty of Health and Social care
within the University of Chester. The approval stipulated
that the study was to be carried out in correspondence
with regional and relevant guidelines.
Data collected from clinicians included clinical eco-
nomic and demographic information, while data collected
from patients included indirect and direct non-medical
resource use, HRQOL (via the EuroQol EQ-5D-3 L), work
productivity impact (via the Work Productivity and
Activity Impairment (WPAI) Questionnaire), and therapy
adherence (via the Morisky Medication Adherence Scale
8-item (MMAS-8)).
Data was collected between December 2014 and April
2015 and captured a period of 12 months retrospectively.
Estimates of healthcare utilisation and costs were then cal-
culated for the 12-month period. The online format of the
CRFs ensured that numeric responses were kept within
reasonable boundaries, and that infeasible responses (such
as the ability to provide two mutually exclusive responses,
for instance) were kept to a minimum. Nevertheless, a
small amount of post-hoc data processing was conducted
based on expert clinical guidance.
Statistical analysis
All direct medical and non-medical costs were sourced
from publically available data (Table 1). Choice of re-
sources to be included in the CHESS study was defined
by the societal and participant/family perspectives [20].
To investigate the distribution of direct costs, resource
use was separated into four categories:
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(1)Ambulatory activity, including: haemophilia-
related visits to haematologists and other
specialists, paramedical practitioners (nurse
specialists, physiotherapists, diet and nutritional
support, etc.), and all tests and procedures
(e.g. blood tests, diagnostic imaging);
(2)Haemophilia-related admissions to hospital, based
on length of stay, including admission to ICU, and
surgical procedure/diagnosis (where applicable):
a. bleed-related hospital admissions; and
b. procedures on ‘target’ joints – defined here as
areas of chronic synovitis [21] – including
arthroscopy, arthrodesis, arthroplasty,
arthrocentesis, and synovectomy;
(3)CFRT; and
(4)Use of a professional (paid) care provider.
All factor consumption was reported by the physician.
For on-demand regimens, factor consumption for the
most recent 3-month period was annualised. For prophy-
laxis regimens, mean IU per infusion was multiplied by
the weekly infusion rate, and annualised.
Direct non-medical and indirect costs were defined
based on seven categories of resource use:
(1)Loss of earnings by the patient (due to absenteeism
and/or early retirement);
(2)Loss of earnings by an informal caregiver (family or
friend) (as above);
(3)Transfer payments (e.g. financial aid, state
allowances);
(4)Over-the-counter (OTC) medications;
(5)Other medical device, personal aid, or home
alteration costs (e.g. walking aids, orthotics);
(6)Alternative therapies (e.g. yoga/Pilates, massage,
nutritionist); and
(7)Transport to/from hospital attendances.
Costs associated with temporary and long-term work
absence (including early retirement) were valued using
the traditional human capital approach (HCA), due to
its benefits in terms of transparency and comparability
versus that of the newer friction cost approach (FCA)
[22]. Patients who reported early retirement due to
haemophilia, or who reported that they were unable to
work due to haemophilia in the 3 months prior to
responding, were costed at the average annual salary
(stratified by country). For patients in employment, days
of work lost due to bleeds across the preceding 3 months
Table 1 National costs for CHESS resource units
Resource item Baseline unit price (EUR)
Francec Germanyd Italye Spainf UKg
Direct costs
Ambulatory care
Haematologist visit (per visit) 25.99–45.99 20.88 27.32–23.17 65.69–113.54 124.71–228.57
Nurse visit (per visit) 81.74 34.28–38.42 15.11 20.92–37.46 19.36
Other specialist visit (per visit) 14.99–45.99 7.30–228.88 18.21–27.32 16.42–160 65.91–612.03
Blood test (per test) 1.89–53.96 0.50–112.50 2.11–17.22 4.78–98.37 4.29–7.67
Other test/examination (per test) 10.79–69.00 5.50–124.60 2.19–134.27 7.49–249.21 1.69–228.24
Drug (per IU)a 0.72 0.85–2.08 0.62–1.23 0.39–0.90 0.44–0.84
Hospitalisation
Target joint (per procedure) 28.81–534.40 12.02–1,719.43 33.48–1,032.91 169.75–2,156.33 1,161.93–8,397.52
Bleed event: ward stay (per day) 290.85 514.29 265 708.71 562.88
Bleed event: ICU stay (per day) 1,174.60 1,265 366 1,559.24 1,056.82
Professional caregiver (per hour) 8.30 27.43 7.39 13.66 24.56
Indirect costsb
Wage (patient/caregiver) (per hour) 24.64 27.15 17 16.35 27.75
Petrol (per mile) 0.53 0.54 0.63 0.50 0.63
Scheduled ambulance (per mile) 1.36 - - - -
Note. Ranges presented where more than one price is possible; ICU: intensive care unit; IU: International Units
aDrug costs sourced via Study Steering Committee liaison and correspondence with domestic drug providers
bCosts for OTC medications, medical devices/aids, alternative therapies, and transfer payment entitlements provided directly by the respondent
cSources: Ameli, sante.gouv, ViDAL.fr, Catalogue Commun des actes médicaux
dSources: Kbv.de, meinpharmaversand.de, Einheitlicher Bewertungsmaßstab, rote-liste service
eSources: AIFA, agenziafarmaco.gov
fSources: Oblikue e-salud, Agencia espanola de medicamentos y productos sanitarios
gSources: National Schedule of Reference Costs, Electronic Medicines Compendium
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was reported and extrapolated. Whilst information regard-
ing comorbidities was captured in the questionnaire, all
direct and indirect costs were limited to those resulting
directly from haemophilia-related activity.
All local currency total costs were converted to Euros
using the official conversion rate as of 30th May, 2015.
Per-patient costs were calculated by multiplying the
quantities of the resource used with the national unit
price of each resource. To extrapolate the sample costs
to country population level, the per-patient costs were
multiplied by national prevalence weights [23]:
−Pix Qi ¼ Costi
−Costix prevalence weights ¼ population cost
−P ¼ price; Q ¼ resource use; and i ¼ 1–n
x wheren ¼ number of cost itemsð Þ
Health-related quality of life
Patient outcomes were obtained by means of the self-
administered EQ-5D-3 L, a non-disease specific instru-
ment covering the areas of mobility, self-care, everyday
activities, pain/discomfort and anxiety/depression [24].
A three-level rating scale is applied to each dimension,
with a total of 245 possible health states defined. The
questionnaire has been validated in many countries in
Europe and is commonly used in economic evaluation
and health technology assessment [25]. The values or
utilities are indicated on a scale on which death has a
value of 0 and perfect health a value of 1, with negative
values being possible. Validated country-specific adult
value sets obtained via the EuroQol website were used,
with the exception of Italy, for which values were taken
from literature [26].
Results
Patients
The demographic data from CHESS are detailed in
Table 2 and the severe haemophilia prevalence data,
which was used for extrapolation of sample costs, are
presented in Table 3. Reports for a total of 1,285 patients
were received – 996 with severe haemophilia A and 289
with severe haemophilia B representing approximately
12% and 21% of the respective populations. 552 patients
(43% of the sample) provided information on indirect
costs and HRQOL via the PSC. Patients were an average
of 35.9 years of age (standard deviation (SD) 14.9), with
the lowest average age in Germany (31.1 years), and the
highest in Italy (38.9 years). The majority of patients
recruited in the study (57%) were receiving CFRT via a
prophylaxis regimen; 5% of patients were diagnosed with
an inhibitor at the time of the study. Coinfection with
HIV and/or HCV was 3% and 5%, respectively. Mean
EQ-5D-3 L index score ranged from 0.59 in the UK to
0.90 in Germany (pooled average 0.76).
Table 2 CHESS demographic data
Country
France (N = 272) Germany (N = 194) Italy (N = 280) Spain (N = 218) UK (N = 321) CHESS (N = 1,285)
PSCs received (%) 199 (73%) 97 (50%) 123 (44%) 96 (44%) 37 (12%) 552 (43%)
Haemophilia subtype (%)
A 202 (74%) 153 (79%) 219 (78%) 176 (81%) 246 (77%) 996 (78%)
B 70 (26%) 41 (21%) 61 (22%) 42 (19%) 75 (23%) 289 (22%)
Age (mean (SD)) 36.3 (13.7) 31.1 (12.0) 38.9 (15.5) 36.0 (14.1) 36.0 (15.9) 35.9 (14.7)
Age categories (%)
18–35 154 (57%) 135 (70%) 142 (51%) 123 (56%) 192 (60%) 746 (58%)
36–59 95 (35%) 52 (27%) 100 (36%) 78 (36%) 91 (28%) 416 (32%)
60+ 23 (8%) 7 (4%) 38 (14%) 17 (8%) 38 (12%) 123 (10%)
Treatment strategy: Prophylaxis (%) 159 (58%) 117 (60%) 143 (51%) 143 (66%) 175 (55%) 737 (57%)
Inhibitor history (%)
Never 225 (83%) 165 (85%) 233 (83%) 179 (82%) 289 (90%) 1,091 (85%)
Previously 29 (11%) 25 (13%) 38 (14%) 27 (12%) 17 (5%) 136 (11%)
Currently 18 (7%) 4 (2%) 9 (3%) 12 (6%) 15 (5%) 58 (5%)
Patients with coinfection (%)
HIV 2 (1%) 4 (2%) 4 (1%) 9 (4%) 19 (6%) 38 (3%)
HCV 7 (3%) 5 (3%) 22 (8%) 15 (7%) 21 (7%) 70 (5%)
EQ-5D-3 L index score (mean (SD)) 0.73 (0.30) 0.90 (0.12) 0.84 (0.12) 0.63 (0.37) 0.59 (0.36) 0.76 (0.28)
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Total economic burden of illness
Total 1-year costs of severe haemophilia for the five
countries was estimated to be EUR 1.55 billion (2014
values) (Table 4), with per-country costs ranging from
EUR 93.8 million in Spain to EUR 700.6 million in
Germany. Annual per-patient costs across the pooled
sample were estimated to be EUR 199,541, ranging from
EUR 129,365 in the UK to EUR 319,024 in Germany.
Direct costs were estimated to be EUR 1.38 billion,
representing approximately 97% of total costs and an
average of EUR 193,363 per annum. Drug expenditure
constitutes the vast majority (97.9%) of direct costs, a
pattern that is found across all five countries (range
95.3–99.4%) (Fig. 1). Total indirect costs for the five
countries were estimated to be EUR 43.3 million, aver-
aging EUR 6,075 per patient across the pooled sample.
Discussion
With an overall population of more than 300 million, the
EU5 is home to approximately 8,123 people with severe
haemophilia A and 1,370 people with severe haemophilia
B. The CHESS study aimed to provide a snapshot view of
the economic, societal, and psychological burden of severe
haemophilia in adults within the EU5. We estimated the
mean per-patient annual direct cost of severe haemophilia
at EUR 173,102, EUR 313,068, EUR 210,025, EUR
132,329, and EUR 116,963 for France, Germany, Italy,
Spain, and the UK, approximately 48, 79, 87, 65, and 34
times higher than the mean per-capita health expenditure
in these countries, respectively [27]. Direct medical re-
source use was the predominant cost driver, with more
than 97% of direct costs taken by CFRT, reflecting previ-
ous research suggesting that costs of CFRT account for
the vast majority of the cost burden [15, 16, 28]. Annual
indirect costs averaged just over EUR 6,000 per patient,
with marginal variation between countries (range EUR
4,850–8,651). The total economic and societal cost of
severe haemophilia in the EU5 in 2014 was estimated at
EUR 1.4 billion.
Patients were recruited to the CHESS study via their
haematologist or HCP, with a response rate of 43% across
the pooled sample. Participation in the study by clinicians
and patients was voluntary, and we therefore cannot rule
out a degree of selection bias. Because the cost of illness
for non-responding patients remains unknown, it is also
not possible to assess the extent of the potential bias. The
ratio of haemophilia A patients relative to that of haemo-
philia B in the CHESS cohort (approximately 1:3.5) is
more narrow than current epidemiological studies, which
place the ratio closer to 1:5 in severe disease [29]. The
differential burden between haemophilia A and B is a
topic of ongoing research; current evidence suggests that
any overrepresentation by haemophilia B may generate
more conservative estimates of disease burden, due to
milder disease symptoms [30].
The proportion of patients receiving prophylaxis in
the study cohort (57%) broadly matches that of a recent
retrospective audit of haemophilia care in the EU5 [31];
prevalence of diagnosed inhibitors (4.5%) is almost iden-
tical to that of a recent study in Portugal (4.7%) [16],
though the study included children (more than half of
inhibitors present before the age of 9 years [32]), as well
as mild and moderate haemophilia patients, who are at
lower risk of inhibitor development [33].
Five percent of the CHESS cohort have recorded HCV
comorbidity, with the highest rate in Italy (8%); results
from the World Federation of Hemophilia Annual Global
Survey [34] suggests that prevalence of HCV among
haemophilia patients is upwards of one in ten, with almost
half of patients in Germany co-diagnosed. Furthermore,
Table 3 Prevalence of severe haemophilia A and B in CHESS countries (all ages)
Country Haemophilia A Haemophilia B
Population (X) [34] Severe (%) (Y)
[43–47]
Est. severe pop.
(X Y)
Population (X) [34] Severe (%) (Y)
[43–45, 47, 48]
Est. severe pop.
(X  Y)
France 5,400 34 1,836 1,201 30 360
Germany 3,422 59 2,019 644 38 245
Italy 3,779 47 1,776 750 37 278
Spain 1,679 33 554 277 33 91
UK 5,646 35 1,976 1,165 34 396
All CHESS countries 8,123 1,370
Table 4 Total economic burden of severe haemophilia in the
EU5 (EUR)
Country Total cost per
country (EUR)
Total per-patient
cost (EUR) (mean
(SD))
Percent of total
healthcare
expenditures in
each country
France 211,414,126 196,117 0.06%
Germany 700,257,680 319,024 0.16%
Italy 269,701,056 220,344 0.12%
Spain 94,010,111 173,771 0.05%
UK 271,278,405 129,365 0.10%
All 1,423,725,035 199,541
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approximately 7% of PWH in the EU5 are HIV-positive
[34–36]; we find prevalence in CHESS to be less than half
this amount. We suggest that a sampling bias towards
non-infected patients may be present to some extent in
this study. The implications of any underrepresentation
for our burden estimates are uncertain: the extent to
which HIV/HCV coinfection impact upon costs of haemo-
philia is of some dispute in current literature [37, 38], but
may be more than 50% higher compared to those with
haemophilia alone.
By profiling consulting patients, we draw from a
cohort of patients who consult more frequently – maybe
because they have difficulty with bleed control, due to
joint degeneration, suboptimal therapy, or adherence. It
is possible, therefore, that our sample is biased towards
those older, more costly, and less adherent patients, and
that our extrapolated costs may be an overestimate of
the actual disease burden. However, the age distribution
of the CHESS cohort is similar to that of another recent
study that sourced data directly from haemophilia treat-
ment centres and data registers across the EU5, Belgium
and Sweden [31].
Our study is limited in its cost estimates by the need to
use publically available reimbursement data, particularly
for hospital admissions, rather than actual costs to hos-
pital providers and patients. Any divergence between
these costs may lead to an under- or over-estimate of the
actual realised costs. Recall bias regarding consultations
and outpatient visits may be present for clinicians,
particularly for consultations with other specialists.
Smaller payments by patients may also be overlooked
when reporting use of devices, aids, and OTC medica-
tions. Costs of informal care provision are limited to that
of the primary caregiver; informal care and household
burden cost estimates were consequently underestimated
for households in which additional individuals contributed
to informal care.
Randomized controlled trials (RCTs) are the gold stand-
ard of evidence generation for health interventions. How-
ever, design of RCTs in rare diseases such as haemophilia is
difficult due to the limited size of the patient population
[39]. Further, there is often disparities between the highly
structured environment of an RCTand ‘real world’ practice,
particularly in the absence of formal clinical guidelines.
Instead, much of the available evidence for rare diseases is
based on larger-scale registries, post-authorisation surveil-
lance studies, and observational studies such as CHESS,
which have in recent years produced major insights
into the treatment and management of individuals
with haemophilia [40].
PWH in the five CHESS countries benefit from major
investment of resources for their care and treatment.
These patients are likely to obtain first access to novel
long-acting and gene-based therapies in haemophilia,
and it is therefore important to understand the continu-
ing unmet need within these populations and where
these new therapies will fit with current treatment ap-
proaches. The estimates of resource use and cost burden
within this study are less translatable outside of Western
Europe, where haemophilia often remains underdiag-
nosed and undertreated [41]. In countries where access
to CFRT is restricted and many PWH experience major
joint damage and deformity by adolescence, the burden
of disease will be weighted more towards the psycho-
social and employment impact resulting from severe
disability and premature mortality [42].
Conclusion
The results of the CHESS study underscore the wide
variety of costs that accompany a rare disease such as
Fig. 1 Distribution of per-patient costs (EUR). Total per-patient costs are shown for each of the five countries as well as a study average split by
CFRT, other direct medical costs, and indirect costs
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haemophilia and the substantial economic burden car-
ried by patients, caregivers, and the health care systems
in these countries. Based on other existing studies of this
patient group, we believe that the cost estimates from
the CHESS cohort extrapolate well to the population of
severe haemophilia patients in the EU5. Though the
costs of CFRT account for the vast majority of the bur-
den in this patient group, the importance of the indirect
impact of haemophilia on the patient and family should
not be overlooked. The CHESS study highlights the ben-
efits of observational study methodologies in capturing a
‘snapshot’ of information for patients with rare diseases.
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